- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03165981
Fever After Simultaneous Versus Sequential Vaccination in Young Children
February 5, 2019 updated by: Duke University
A Prospective, Randomized, Open-label Clinical Trial to Assess Fever Following Simultaneous Versus Sequential Administration of PCV13, DTaP Vaccine and IIV in Young Children
A prospective, randomized open-label clinical trial that will be conducted during the 2017-2018 influenza season.
During the 2017-2018 season, approximately 280 children will be enrolled at Duke University Medical Center and Kaiser Permanente Northern California.
Eligible children will be randomized to receive simultaneous or sequentially administered US licensed PCV13, US-licensed DTaP vaccine, and US-licensed inactivated influenza vaccine (IIV).
Children in the simultaneous group will receive PCV13, DTaP, and IIV vaccines at Visit 1, and then return for a health education visit without vaccination about 2 weeks later (Visit 2).
Children in the sequential group will receive both PCV13 and DTaP without IIV at Visit 1, and then will receive IIV and health education about 2 weeks later (Visit 2).
Parents will record the occurrence of fever, solicited adverse events, medical care utilization, and receipt of antipyretics over 8 days following Visit 1 and Visit 2. In addition, febrile seizures and serious adverse events will be recorded for the entire study period (from enrollment through 8 days following the Visit 2) as determined through parental report and chart review.
Parental perceptions about their child's vaccine schedule will be assessed on the 8th day following Visit 2.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
221
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Oakland, California, United States, 94612
- Kaiser Permanente Northern California
-
-
Georgia
-
Atlanta, Georgia, United States, 30333
- Centers for Disease Control and Prevention
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 12 through 16 months of age (i.e. from the 1-year birthday until the day before 17 months of age) at the time of vaccination
- Stable health as determined by investigator's clinical examination and assessment of child's medical history
- Has received all immunizations recommended by Advisory Committee for Immunization Practices (ACIP) during the first year of life with the exception of rotavirus and influenza vaccines.
- The parent(s)/ legally authorized representative(s) LAR(s) intend for the child to receive DTaP and PCV13 in addition to this season's IIV
- The parent(s)/LAR(s) must be willing and capable of providing permission for their child to participate through the written informed consent process
- The parent(s)/LAR(s) must be able to comply with the requirements of the protocol (e.g., completion of the memory aid (either electronic or paper diary), return for follow-up visits, respects intervals between the visits and have telephone access.
- The parent(s)/LAR(s) must be English speaking
- The parent(s)/LAR(s) must agree to sign a medical release for the child so that study personnel may obtain medical information about the child's health (if needed)
Exclusion Criteria:
- History of any seizure (including febrile seizure) in the child or a febrile seizure in a first degree relative
- Has already completed influenza vaccination during the current season per ACIP recommendations
- Receipt of more than 3 previous doses of DTaP
- Received the 3rd dose of DTaP within 6 months of Visit 1
- Receipt of more than 3 previous doses of PCV13
- Received the 3rd dose of PCV13 within 8 weeks of Visit 1
- History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any influenza, diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or pneumococcal vaccine.
- History of a severe allergic reaction (e.g., anaphylaxis) to any component (including egg protein) of any of the three vaccines used in this study; or a latex allergy.
- History of Guillain-Barré syndrome within 6 weeks following a prior dose of influenza, DTaP, or tetanus toxoid containing vaccine
- History of a progressive neurologic disorder
- History of encephalopathy within 7 days of a previous pertussis-containing vaccine
- History of collapse within 3 days after a prior dose of DTaP
- Received any other licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Visit 1
- Received an experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 28 days prior to Visit 1, or expects to receive an experimental/investigational agent during the study period (up to 8 days after visit 2)
- A moderate to severe acute illness within 72 hours of Visit 1
- A reported temperature greater than or equal to 100.4°F (38.0°C) within 72 hours prior enrollment or a temperature (measured by temporal artery thermometer) greater than or equal to 100.4°F (38.0°C) at the time of enrollment
- Receipt of an antipyretic medication (acetaminophen or ibuprofen) within 24 hours prior to enrollment
- Parent(s)/LAR is planning to administer a prophylactic antipyretic or medication on the day of, and/or within 7 days following Visit 1 or Visit 2
- Long term (at least 14 consecutive days) oral corticosteroids (prednisone 2 mg/kg/day or equivalent other glucocorticoid), any parenteral steroids, high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) or other immune-modifying drugs or immunosuppressants within the preceding 6 months prior to Visit 1
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and or their provider's routine physical examination
- Has an active neoplastic disease, a history of any hematologic malignancy, current bleeding disorder, or taking anticoagulants.
- Unable to receive an intramuscular injection in the thigh
- Any condition deemed by the investigator to place the child at increased risk as a result of their participation in the study
- Any child or grandchild of a study investigator or study team member
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Simultaneous vaccination arm
In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1.
Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
|
ACIP Recommended vaccine
Other Names:
ACIP Recommended vaccine
Other Names:
ACIP Recommended vaccine
Other Names:
|
OTHER: Sequential vaccination arm
In the study arm, subjects will receive PCV13 and DTaP during study visit 1.
Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
|
ACIP Recommended vaccine
Other Names:
ACIP Recommended vaccine
Other Names:
ACIP Recommended vaccine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Fever Following Vaccination
Time Frame: 2 days post administration
|
Proportion of children with fever (temperature ≥ 38.0°C or ≥ 100.4°F) on day 1 and/or day 2 following Visit 1 and/or Visit 2.
|
2 days post administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Fever Visit 1
Time Frame: 2 days post administration
|
Proportion of children with fever (temperature ≥ 38.0°C or ≥ 100.4°F) on day 1 and/or day 2 following Visit 1
|
2 days post administration
|
Number of Participants With Fever Visit 2
Time Frame: 2 days post administration
|
Proportion of children with fever (temperature ≥ 38.0°C or ≥ 100.4°F) on day 1 and/or day 2 following Visit 2
|
2 days post administration
|
Number of Participants With Grade 2 and/or 3 Following Visit 1
Time Frame: 2 days post administration
|
Proportions of children with moderate/severe fever (Grade 2 and/or 3) on day 1 and/or day 2 following Visit 1. (Moderate/severe fever: ≥ 38.6°C or ≥ 101.4°F)
|
2 days post administration
|
Number of Participants With Grade 2 and/or 3 Following Visit 2
Time Frame: 2 days post administration
|
Proportions of children with moderate/severe fever (Grade 2 and/or 3) on day 1 and/or day 2 following Visit 2.
|
2 days post administration
|
Number of Participants With Grade 2 and/or 3 Following Visit 1 and Visit 2
Time Frame: 2 days post administration
|
Proportions of children with moderate/severe fever (Grade 2 and/or 3) on day 1 and/or day 2 following Visit 1 and Visit 2 combined.
|
2 days post administration
|
Duration of Fever - Visit 1
Time Frame: 8 days post administration
|
Average number of consecutive days of fever (temperature ≥ 38.0°C or ≥ 100.4°F) per subject for fever starting on day 1 or 2 following Visit 1. Note: fever starting on day 1 or 2 could continue through day 8.
|
8 days post administration
|
Duration of Fever - Visit 2
Time Frame: 8 days post administration
|
Average number of consecutive days of fever (temperature ≥ 38.0°C or ≥ 100.4°F) per subject for fever starting on day 1 or 2 following Visit 2. Note: fever starting on day 1 or 2 could continue through day 8.
|
8 days post administration
|
Duration of Fever - Visit 1 and 2 Combined
Time Frame: 8 days post administration
|
Average number of consecutive days of fever (temperature ≥ 38.0°C or ≥ 100.4°F) per subject for fever starting on day 1 or 2 following and Visit 1 and Visit 2 combined.
Note: fever starting on day 1 or 2 could continue through day 8.
|
8 days post administration
|
Number of Participants With Medical Care Utilization - Visit 1
Time Frame: 2 days post administration
|
Proportion of children with medical care utilization (telephone call, medical office visit, emergency department visit, or hospital admission) for fever on day 1 and/or day 2 following Visit 1.
|
2 days post administration
|
Number of Participants With Medical Care Utilization - Visit 2
Time Frame: 2 days post administration
|
Proportion of children with medical care utilization (telephone call, medical office visit, emergency department visit, or hospital admission) for fever on day 1 and/or day 2 following Visit 2.
|
2 days post administration
|
Number of Participants With Medical Care Utilization - Visit 1 and 2 Combined
Time Frame: 2 days post administration
|
Proportion of children with medical care utilization (telephone call, medical office visit, emergency department visit, or hospital admission) for fever on day 1 and/or day 2 following Visit 1 and Visit 2 combined.
|
2 days post administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Emmanuel B Walter, MD, MPH, Duke University
- Principal Investigator: Nicola Klein, MD, PhD, Kaiser Permanente
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 25, 2017
Primary Completion (ACTUAL)
January 15, 2018
Study Completion (ACTUAL)
January 15, 2018
Study Registration Dates
First Submitted
May 23, 2017
First Submitted That Met QC Criteria
May 23, 2017
First Posted (ACTUAL)
May 24, 2017
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2019
Last Update Submitted That Met QC Criteria
February 5, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00082484
- 200 2012 53663 0009 (OTHER_GRANT: CDC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fever
-
Meir Medical CenterCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
U.S. Army Medical Research and Development CommandBausch Health Americas, Inc.WithdrawnCrimean-Congo Hemorrhagic Fever | Lassa FeverGermany
-
The Scientific and Technological Research Council...MonitorCROCompleted
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
Tongji HospitalRecruitingHFRS (Hemorrhagic Fever With Renal Syndrome)China
-
Shaare Zedek Medical CenterCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
Carina Mari ApariciWithdrawnFever of Unknown OriginUnited States
Clinical Trials on DTaP
-
China National Biotec Group Company LimitedPeking University; Beijing Institute of Biological Products Co Ltd.; Sichuan... and other collaboratorsCompleted
-
China National Biotec Group Company LimitedPeking University; Beijing Institute of Biological Products Co Ltd.; Sichuan... and other collaboratorsUnknown
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Hubei Provincial Center for... and other collaboratorsUnknown
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological... and other collaboratorsUnknown
-
KEMRI-Wellcome Trust Collaborative Research ProgramUniversity of Colorado, Denver; GlaxoSmithKline; University of Oxford; Kenya Ministry...Unknown
-
Boryung Pharmaceutical Co., LtdCompletedPertussis | Tetanus | Diphtheria | PoliomyelitisThailand, Korea, Republic of
-
Jiangsu Province Centers for Disease Control and...Completed
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
SanofiCompletedPertussis | Tetanus | Diphtheria | PoliomyelitisKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedStudy of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsHepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type bPeru